ADMA Biologics (NASDAQ:ADMA) saw its stock price plummet 5.55% in after-hours trading on Wednesday, following the release of its first-quarter earnings report that fell short of analyst expectations. The biopharmaceutical company, which focuses on developing and commercializing specialty plasma-derived products, reported mixed results that disappointed investors despite showing significant year-over-year growth.

For the first quarter, ADMA Biologics reported adjusted earnings per share of $0.14, missing the analyst consensus estimate of $0.16 by 12.5%. While this represents a 75% increase from the $0.08 per share reported in the same period last year, it wasn't enough to meet market expectations. Revenue for the quarter came in at $114.80 million, falling short of the projected $116.40 million by 1.37%. Despite the miss, this figure still marks a robust 40.22% increase from the $81.88 million recorded in the previous year's quarter.

In an attempt to boost investor confidence, ADMA Biologics announced a $500 million share repurchase program alongside its earnings release. The company also raised its revenue guidance for fiscal years 2025 and 2026 to over $500 million and $625 million, respectively. Furthermore, ADMA projects its total annual revenues to exceed $1.1 billion by 2030. However, these positive long-term projections were overshadowed by the immediate reaction to the earnings miss, highlighting the market's focus on short-term performance metrics.